Cited by 604Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsMedical Imaging Techniques and Applications

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study

Open access

Sabri, Osama, Sabbagh, Marwan N., Seibyl, John, Barthel, Henryk, Akatsu, Hiroyasu, Ouchi, Yasuomi, Senda, Kohei, Murayama, Shigeo, Ishii, Kenji, Takao, Masaki, Beach, Thomas G., Rowe, Christopher C., Leverenz, James B., Ghetti, Bernardino, Ironside, James W., Catafau, Ana M., Stephens, Andrew W., Mueller, Andre, Koglin, Norman, Hoffmann, Anja, Roth, Katrin, Reininger, Cornelia, Schulz‐Schaeffer, Walter J., Florbetaben Phase 3 Study Group·2015·Alzheimer's & Dementia

DOI 10.1016/j.jalz.2015.02.004

Open this paper in CoChat — free account Open PDF

Abstract

Background: Evaluation of brain β‐amyloid by positron emission tomography (PET) imaging can assist in the diagnosis of Alzheimer disease (AD) and other dementias. Methods: Open‐label, nonrandomized, multicenter, phase 3 study to validate the 18 F‐labeled β‐amyloid tracer florbetaben by comparing in vivo PET imaging with post‐mortem histopathology. Results: Brain images and tissue from 74 deceased subjects (of 216 trial participants) were analyzed. Forty‐six of 47 neuritic β‐amyloid‐positive cases were read as PET positive, and 24 of 27 neuritic β‐amyloid plaque‐negative cases were read as PET negative (sensitivity 97.9% [95% confidence interval or CI 93.8–100%], specificity 88.9% [95% CI 77.0–100%]). In a subgroup, a regional tissue‐scan matched analysis was performed. In areas known to strongly accumulate β‐amyloid plaques, sensitivity and specificity were 82% to 90%, and 86% to 95%, respectively. Conclusions: Florbetaben PET shows high sensitivity and specificity for the detection of histopathology‐confirmed neuritic β‐amyloid plaques and may thus be a valuable adjunct to clinical diagnosis, particularly for the exclusion of AD. Trial registration: ClinicalTrials.gov NCT01020838 .

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.jalz.2015.02.004

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Statistical Methods for Rates and Proportions
Fleiss, J. L., Levin, B., & Paik, M. C. (2003) · Wiley Series in Probability and Statistics · doi:10.1002/0471445428 · Cited by 18,646
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 4×
“Middle frontal gyrus Intense [19] 18/21 (85.”
Influential
Statistical Methods for Rates and Proportions.
Everitt, B. S., & Fleiss, J. L. (1981) · Biometrics · doi:10.2307/2530193 · Cited by 9,034
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): Part II. Standardization of the neuropathologic assessment of Alzheimer's disease
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Self-citation
National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease
Hyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092
Self-citation
Consortium to Establish a Registry for Alzheimer's Disease (CERAD)
Fillenbaum, G., & Heyman, A. (2002) · doi:10.1002/0470846410.ch42(iii · Cited by 2,859
Revising the definition of Alzheimer's disease: a new lexicon
Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., DeKosky, S. T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N. C., Galasko, D., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70223-4 · Cited by 1,869
Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates.
Scheltens, P., Leys, D., Barkhof, F., Huglo, D. G., Weinstein, H. C., Vermersch, P., Kuiper, M. A., Steinling, M., Wolters, E. C., & Valk, J. (1992) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.10.967 · Cited by 1,811
Use of Florbetapir-PET for Imaging β-Amyloid Pathology
Clark, C. M. (2011) · JAMA · doi:10.1001/jama.2010.2008 · Cited by 1,117

Show all 33 references

Sorted by citations

Items 401–500 of 604

Aβ Imaging in Aging, Alzheimer’s Disease and Other Neurodegenerative Conditions
Villemagne, V. L., Fodero‐Tavoletti, M. T., Yates, P. A., Masters, C. L., & Rowe, C. C. (2014) · Springer eBooks · doi:10.1007/978-3-642-54307-4_10 · Cited by 4
Self-citation
Molekulare Bildgebung bei neurologischen Erkrankungen
Reimold, M., & la Fougère, C. J. (2016) · Der Radiologe · doi:10.1007/s00117-016-0124-8 · Cited by 4
Yes we can analyse amyloid images - Now What?
Barthel, H., Seibyl, J. P., & Sabri, O. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3644-1 · Cited by 4
Self-citation
Current Knowledge and Clinical Application of Brain Imaging in Alzheimer's Disease
Kang, D. W., & Lim, H. K. (2018) · 신경정신의학 · doi:10.4306/jknpa.2018.57.1.12 · Cited by 4
Amyloid Deposits and Idiopathic Normal-Pressure Hydrocephalus: An 18F-Florbetaben Study
Kang, K., Yoon, U., Hong, J., Jeong, S. Y., Ko, P., Lee, S., & Lee, H. (2018) · European Neurology · doi:10.1159/000487133 · Cited by 4
Una revisión de técnicas básicas de neuroimagen para el diagnóstico de enfermedades neurodegenerativas.
Rueda, A., & Luis Fernando Enríquez, S. (2018) · Biosalud · doi:10.17151/biosa.2018.17.2.5 · Cited by 10
Correlation Between Amyloid PET Imaging and Discordant Cerebrospinal Fluid Biomarkers Results in Patients with Suspected Alzheimer’s Disease
Lojo-Ramírez, J. A., Guerra-Gómez, M., Marín-Cabañas, A. M., Fernández‐Rodríguez, P., Sánchez‐Arjona, M. B., Macías, E. F., & García-Solís, D. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230744 · Cited by 3
The Impact of Amyloid and Tau PET on Alzheimer Disease Diagnostics: AJR Expert Panel Narrative Review
Nasrallah, I. M., Kuo, P. H., Nordberg, A. K., Bohnen, N. I., & Ponisio, M. R. (2025) · American Journal of Roentgenology · doi:10.2214/ajr.24.32325 · Cited by 4
Integrating individualized connectome with amyloid pathology improves predictive modeling of future cognitive decline
He, H., Razlighi, Q. R., Gazes, Y., Habeck, C. G., Stern, Y., Initiative, A. D. N., Weiner, M. W., Aisen, P. S. S., Petersen, R. C., Jack, C. R., et al. (2025) · Communications Medicine · doi:10.1038/s43856-025-01170-5 · Cited by 5
Degenerative pathologies on cortical biopsy, dopaminergic depletion, and shunt efficacy in iNPH
Ye, B. S., Park, S. H., Jeon, S., Kang, S. W., Kim, S. H., & Chang, W. S. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70974 · Cited by 3
Automated quantification of brain PET in PET/CT using deep learning-based CT-to-MR translation: a feasibility study
Kim, D., Choo, K., Lee, S., Kang, S., Yun, M., & Yang, J. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07132-2 · Cited by 3
Linking genomic and proteomic signatures to brain amyloid burden: insights from GR@ACE/DEGESCO
Puerta, R., de Rojas, I., García‐González, P., Olivé, C., Sotolongo‐Grau, Ó., García‐Sánchez, A., García‐Gutiérrez, F., Montrreal, L., Tartari, J. P., Sanabria, Á., et al. (2025) · Functional & Integrative Genomics · doi:10.1007/s10142-025-01581-6 · Cited by 4
Tau-PET Bildgebung der Demenzerkrankungen
Bischof, G. N. (2022) · Angewandte Nuklearmedizin · doi:10.1055/a-1712-6020 · Cited by 2
Transforming Neurology and Psychiatry
Taha, A., Alassi, A., GJEDDE, A. H., & Wong, D. F. (2023) · PET Clinics · doi:10.1016/j.cpet.2023.06.002 · Cited by 3
Clinical and Pathological Validation of CT-Based Regional Harmonization Methods of Amyloid PET
Kim, S.-J., Jang, H., Yoo, H., Na, D. L., Ham, H., Kim, H. J., Kim, J. P., Farrar, G., Moon, S. H., & Seo, S. W. (2023) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000004937 · Cited by 3
Patterns of Focal Amyloid Deposition Using 18F-Florbetaben PET in Patients with Cognitive Impairment
Chung, S.-E., Kim, H., Jo, S., Lee, S., Lee, Y., Roh, J. H., & Lee, J. (2022) · Diagnostics · doi:10.3390/diagnostics12061357 · Cited by 4
Symptomatic and preclinical Alzheimer’s disease: Neuropathology and imaging
Thal, D. R. (2016) · Neurology Psychiatry and Brain Research · doi:10.1016/j.npbr.2016.01.001 · Cited by 3
Validation of a spatial normalization method using a principal component derived adaptive template for [18F]florbetaben PET.
Leuzy, A., Heurling, K., Santi, S. D., Bullich, S., Hansson, O., & Lilja, J. (2020) · PubMed Central · Cited by 3
Amyloid Imaging in Dementia and Neurodegenerative Disease
Ponisio, M. R., Iranpour, P., & Benzinger, T. L. S. (2021) · Springer eBooks · doi:10.1007/978-3-030-82367-2_11 · Cited by 4
Biomarkers of Disorders of the Nervous System
Jain, K. K. (2017) · Springer eBooks · doi:10.1007/978-1-4939-7431-3_14 · Cited by 3
The Value of Positron Emission Tomography for Confirmation of Alzheimer’s Disease in the Era of Amyloid-Targeting Therapies
Veljanoska, E., Gomes, S., Szende, Á., Cabra, A., Munter-Young, R., & Gordois, A. (2025) · Value in Health · doi:10.1016/j.jval.2025.02.011 · Cited by 2
Sequential scans of 18F-flutemetamol PET using PET/CT and PET/MRI: influence of amyloid burden, scan interval, and age
Morooka, S., Fushimi, Y., Okuchi, S., Sakata, A., Yamamoto, T., Nakajima, S., Mitsumoto, K., Itagaki, K., Kubota, M., Shima, A., et al. (2025) · Japanese Journal of Radiology · doi:10.1007/s11604-025-01915-1 · Cited by 2
EEG-based detection of early functional brain changes in subjective cognitive decline: a prospective cohort study
Ryoo, N., Park, J., Lee, C., Ho, S. H., Hong, Y. J., Jeong, J. H., Park, K. H., Wang, M. J., Choi, S. H., Kim, S., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01875-8 · Cited by 2
Hand Grip Strength Predicts Cognitive Decline in Subjective Cognitive Decline: 2-Year Follow-Up Results
Lim, E. Y., Hong, Y. J., Jeong, J. H., Park, K. H., Kim, S., Wang, M. J., Shim, Y., Choi, S. H., & Yang, D. W. (2026) · Journal of Korean Medical Science · doi:10.3346/jkms.2026.41.e36 · Cited by 2
Relationship between age and severity of cognitive impairment at diagnosis for early‐onset and late‐onset Alzheimer's disease: Comparison of LEADS and ADNI
Hammers, D. B., Eloyan, A., Thangarajah, M., Taurone, A., Gao, S., Beckett, L. A., Kirby, K., Dage, J. L., Nudelman, K. N. H., Aisen, P. S. S., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71160 · Cited by 2
Comparability of Centiloid values from [18F]flutemetamol scans using seven commercial and research software
Bollack, A., Schwarz, A. J., Bourgeat, P., Doré, V., Fripp, J., Page, C., Bonke, E. M., Thurfjell, L., Hass, M., Balhorn, W., et al. (2026) · Neuroimage Reports · doi:10.1016/j.ynirp.2026.100343 · Cited by 2
Impact of Tracer Retention Levels on Visual Analysis of Cerebral [18F]- Florbetaben Pet Images
Giovacchini, G., Giovannini, E., Borsò, E., Lazzeri, P., Duce, V., Ferrando, O., Foppiano, F., & Ciarmiello, A. (2020) · Current Radiopharmaceuticals · doi:10.2174/1874471013666200729155717 · Cited by 2
Case report: Non-Alzheimer's disease tauopathy with logopenic variant primary progressive aphasia diagnosed using amyloid and tau PET
Momota, Y., Konishi, M., Takahata, K., Kishimoto, T., Tezuka, T., Bun, S., Tabuchi, H., Ito, D., & Mimura, M. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.1049113 · Cited by 3
Les phases prodromique et préclinique de la maladie d’Alzheimer
Planche, V., & Villain, N. (2024) · Pratique Neurologique - FMC · doi:10.1016/j.praneu.2024.01.005 · Cited by 2
Novel β-amyloid PET Imaging Study of [18F]92 in Patients with Cognitive Decline
Ni, M., Zhu, X., Wang, K., Guo, W., Shi, Q., Li, Y., Cui, M., & Xie, Q. (2024) · ACS Omega · doi:10.1021/acsomega.4c03412 · Cited by 2
Ultra-fast [18F]florbetapir PET imaging using the uMI Panorama PET/CT system
Yang, X., Wu, M., Liang, M., Zhang, H., Li, B., Mao, C., Dong, L., Wang, Y., Xing, H., Ren, C., et al. (2024) · EJNMMI Physics · doi:10.1186/s40658-024-00712-5 · Cited by 2
Evaluating 18F-Florzolotau tau PET for Alzheimer’s disease diagnosis with 18F-Flortaucipir as reference
Zhang, Q., Lu, J., Wang, L., Jiao, F., Wang, M., Shi, K., Zuo, C., Jiang, J., & Initiative, A. D. N. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13342-3 · Cited by 2
Use of Imaging for Preclinical Evaluation
Wang, Z. J., Chang, T. T. A., & Slauter, R. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803620-4.00035-9 · Cited by 2
Orientation of a Diagnostic Ligand Bound to Macroscopically Aligned Amyloid-β Fibrils Determined by Solid-State NMR
Townsend, D. J., Hughes, E., Stewart, K. L., Griffin, J. M., Radford, S. E., & Middleton, D. A. (2018) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.8b02448 · Cited by 2
Caudate-anchored cognitive connectivity pursuant to orthostatic hypotension in early Parkinson's disease
Yoo, S., Ha, S., Oh, Y., Ryu, D.-W., Yoo, J.-Y., Lee, K.-S., & Kim, J. (2022) · Scientific Reports · doi:10.1038/s41598-022-26811-w · Cited by 2
Development of a home-based cognitive test for cognitive monitoring in subjective cognitive decline with high risk of Alzheimer’s disease
Hong, Y. J., Lee, S. B., Kim, S., Lee, M. A., Park, J. W., & Yang, D. W. (2023) · Medicine · doi:10.1097/md.0000000000033096 · Cited by 2
Acceleration of high-quality Raman imaging via a locality enhanced transformer network
Weng, S., Zhu, R., Wu, Y., Wang, C., Li, P., Zheng, L., Liang, D., & Duan, Z. (2023) · The Analyst · doi:10.1039/d3an01543b · Cited by 2
Elevated Amyloid-β PET Scan and Cognitive and Functional Decline in Mild Cognitive Impairment and Dementia of Uncertain Etiology
Plassman, B., Ford, C. B., Smith, V. A., DePasquale, N., Burke, J. R., Korthauer, L. E., Ott, B. R., Bélanger, E., Shepherd-Banigan, M., Couch, E., et al. (2024) · Journal of Alzheimer's Disease · doi:10.3233/jad-230950 · Cited by 2
PET Imaging Agents for Alzheimer’s Disease
Choi, S., Plöessl, K., Zhu, L., & Kung, H. F. (2017) · Topics in medicinal chemistry · doi:10.1007/7355_2016_18 · Cited by 2
The neuroscience of dementia
Hatashita, S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815854-8.00019-7 · Cited by 2
Identification of Alzheimer’s Disease by Molecular Imaging: Progress and ProspectsPreprint
Xing, L., Lv, X., Guo, Y., Jiang, C., Li, M., Yang, M., Guo, R., Zhu, X., Li, X., Shi, H., et al. (2024) · Preprints.org · doi:10.20944/preprints202401.0477.v1 · Cited by 2
Prionopathies and Prionlike Protein Aberrations in Neurodegenerative Diseases
Anderson, K. N., Overcast, W. B., Brosch, J. R., Graner, B. D., & Veronesi, M. C. (2021) · Neurographics · doi:10.3174/ng.2000035 · Cited by 1
Aβ Imaging in Aging, Alzheimer’s Disease, and Other Neurodegenerative Conditions
Villemagne, V. L., Doré, V., Burnham, S. C., & Rowe, C. C. (2020) · Springer eBooks · doi:10.1007/978-3-030-53168-3_10 · Cited by 2
Self-citation
Simple Synthesis of [18F] AV-45 and its Clinical Application in the Diagnosis of Alzheimer's Disease
Zhang, Q., Yilihamu, N., Li, Y., Li, X.-H., & Qin, Y. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867331666230731123226 · Cited by 1
Classification of Alzheimer Disease using Machine Learning Algorithm
Dasu, M. V., Priyanka, C., Tejaswini, G., Ramana, J. V., Suleman, D., & Sai, S. S. S. (2024) · International Conference on Automation and Computation (AUTOCOM) · doi:10.1109/autocom60220.2024.10486165 · Cited by 3
Longitudinal Analysis of Objective and Self-Reported Cognitive Functions in Individuals with Subjective Cognitive Decline
Ryu, S. Y., Lee, C., Ho, S. H., Hong, Y. J., Jeong, J. H., Park, K. H., Wang, M. J., Choi, S. H., Kim, S., & Yang, D. W. (2025) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000543230 · Cited by 1
Centiloid values from deep learning-based CT parcellation: a valid alternative to freesurfer
Yoon, Y. J., Seo, S., Lee, S., Lim, H., Choo, K., Kim, D., Han, H., So, M., Kang, H., Kang, S., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01860-1 · Cited by 1
Salivary Gland Uptake on 18 F‐Florbetaben PET Did Not Demonstrate Additional Diagnostic Value for Alzheimer's Disease
Kwon, H. W., Jung, S., Shin, C., Kim, J. H., & Park, M. H. (2026) · Brain and Behavior · doi:10.1002/brb3.71199 · Cited by 1
Association of White Matter Hyperintensities, Regional Brain Glucose Metabolism, and Cognitive Impairment in Aβ-Negative Patients
So, M., Seo, S., Kim, D., Lee, S., Lim, H., Yoon, Y. J., Kim, D., Han, H., Jun, Y., Seo, D., et al. (2026) · Neurology · doi:10.1212/wnl.0000000000214772 · Cited by 1
Dietary Intake of n-6 Polyunsaturated Fatty Acid Is Associated With Alzheimer’s Disease Pathology in a Memory Clinic Population
Pyo, B.-J., Lee, J., Lee, H. A., Won, K. S., & Kim, H. W. (2026) · Topics in Clinical Nutrition · doi:10.1097/tin.0000000000000416 · Cited by 1
Circulating Sphingomyelins Correlate With Plasma T‐Tau in Cognitively Unimpaired Older Adults at Risk of Developing Alzheimer's Disease
Sharmin, T., Doecke, J. D., Chatterjee, P., Pedrini, S., Sohrabi, H. R., Ashton, N. J., Zetterberg, H., Garg, M. L., Blennow, K., & Martins, R. N. (2026) · Journal of Neurochemistry · doi:10.1111/jnc.70436 · Cited by 1
First-in-Human Imaging Results of PHAROS: A Versatile High-Resolution TOF/DOI PET Scanner for Brain, Breast, and Extremity Imaging
Ko, G. B., Kim, K. Y., Kang, S. K., Lee, J., Jung, R., Kwak, D. J., Son, J., Shin, S. A., Ryoo, H. G., Kang, Y.-K., et al. (2026) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.271172 · Cited by 1
Impact of adjunctive quantitative analysis on visual interpretation of amyloid PET: a multiple tracer, multicentre study
Ha, S., Choi, B., Kwon, S. J., Kang, S., Son, J., Jeong, S. Y., Lee, S.-W., Choe, Y. S., Kim, D., & Hong, C. M. (2026) · European Radiology · doi:10.1007/s00330-026-12687-1 · Cited by 1
Clinical Evaluation of the Revised Biological and Clinical Staging Criteria for Alzheimer Disease in China
Wang, Z.-Y., Xin, J.-W., Wang, M., Chen, S., Chen, K., Lu, J., Huang, Y., Zhang, W., Huang, W., Wang, R., et al. (2026) · Neurology · doi:10.1212/wnl.0000000000218184 · Cited by 1
Comparative Prognostic Performance of Hippocampal Volume and Plasma Biomarkers in Amyloid-Negative Subjective Cognitive Decline: A Four-Year Follow-up
Yoon, B., Lee, H.-J., Hong, Y. J., Park, K. H., Kim, S., Wang, M. J., Choi, S. H., Kang, S., Jeong, J. H., & Yang, D. W. (2026) · Journal of Clinical Neurology · doi:10.3988/jcn.2025.0659 · Cited by 1
Texture-Based Analysis of 18F-Labeled Amyloid PET Brain Images
Seiffert, A. P., Gómez‐Grande, A., Milara, E., Velasco, S. L., Villarejo‐Galende, A., Aguilera, E. J. G., & González, P. S. (2021) · Applied Sciences · doi:10.3390/app11051991 · Cited by 2
Piramal Imaging
Dinkelborg, L. M. (2015) · Neurodegenerative Disease Management · doi:10.2217/nmt.15.26 · Cited by 1
Diagnostic Uses of Radiopharmaceuticals in Nuclear Medicine
Saha, G. B. (2017) · Springer eBooks · doi:10.1007/978-3-319-57580-3_13 · Cited by 1
Influence of amyloid and diagnostic syndrome on non‐traditional memory scores in early‐onset Alzheimer's disease
Bushnell, J., Hammers, D. B., Aisen, P. S. S., Dage, J. L., Eloyan, A., Foroud, T., Grinberg, L. T., Iaccarino, L., Jack, C. R., Kirby, K., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13434 · Cited by 2
Neuroimaging Biomarkers in Alzheimer’s Disease and Related Disorders
Masdeu, J. C., & Pascual, B. (2023) · Springer eBooks · doi:10.1007/978-3-031-43356-6_11 · Cited by 1
Cognitive Aging and the Transition to Early Alzheimer’s Disease
Mormino, E. C., & Jagust, W. J. (2024) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780190917982.013.59 · Cited by 1
Plasma amyloid beta biomarkers predict amyloid positivity and longitudinal clinical progression in mild cognitive impairment
Ataka, T., Kimura, N., Kaneko, N., Masuda, T., Takeuchi, Y., Yabuuchi, K., Mizukami, T., Takeuchi, T., Ito, T., Tasai, H., et al. (2024) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70008 · Cited by 1
IC‐P‐007: Clinical utility of amyloid imaging in the differential diagnosis of atypical/unclear dementias and its impact on caregivers
Bensaïdane, M. R., Bouchard, R. W., Fortin, M., Houde, M., Rosa‐Neto, P., Poulin, S. P., Verret, L., Soucy, J., Beauregard, J., & Laforce, R. J. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.06.027 · Cited by 1
Neuroimaging Advances in Alzheimer's Disease
Schonhaut, D. R., & Rabinovici, G. D. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800105-9.00017-2 · Cited by 1
Apolipoprotein E4: A Risk Factor for Successful Cognitive Aging
Kwon, O. D. (2016) · Dementia and Neurocognitive Disorders · doi:10.12779/dnd.2016.15.3.61 · Cited by 1
Negative 11C-PIB PET Predicts Lack of Alzheimer’s Disease Pathology in Postmortem Examination
Scheinin, N. M., Gardberg, M., Röyttä, M., & Rinne, J. O. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170569 · Cited by 1
L’imagerie moléculaire de la maladie d’Alzheimer et des maladies apparentées
Semah, F. (2018) · Médecine Nucléaire · doi:10.1016/j.mednuc.2018.03.132 · Cited by 1
The Prevalence of Rapid Eye Movement Sleep Behavior Disorder in Amyloid Positron Emission Tomography Positive Alzheimer’s Disease
Kim, H., Lee, H. J., Shin, D.-J., Lee, Y., Noh, Y., & Park, K. H. (2019) · Journal of Sleep Medicine · doi:10.13078/jsm.190046 · Cited by 1
Case 2: Alzheimer’s Disease—[18F]FDG, Tau, and Amyloid PET
Arbizu, J., & Bastidas, J. F. (2021) · Springer eBooks · doi:10.1007/978-3-030-83598-9_2 · Cited by 1
Optimization of Automatic Synthesis and Separation of [18F] AV-45 and Quality Control
Zhang, Q., Li, Y., Yilihamu, N., Li, X.-H., Ba, Y., & Qin, Y. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2022.826678 · Cited by 1
Neurodegeneration Imaging
Barthel, H., & Sabri, O. (2017) · Springer eBooks · doi:10.1007/978-3-319-69641-6_7 · Cited by 1
Self-citation
Recent Updates on PET Imaging in Neurodegenerative Diseases
Kim, Y. K. (2022) · Journal of the Korean Society of Radiology · doi:10.3348/jksr.2022.0052 · Cited by 1
Proven validity and management impact of amyloid imaging in Alzheimer’s disease—repetita juvant
Barthel, H., Arbizu, J., Drzezga, A. E., Garibotto, V., Lammertsma, A. A., & Morbelli, S. D. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04742-w · Cited by 1
Self-citation
Aβ-affine bifunctional copper chelators capable of Aβ-induced oxidative stress reduction and amyloid disaggregationPreprint
Krasnovskaya, O. O., Abramchuk, D., Vaneev, A. N., Gorelkin, P. V., Abakumov, M. A., Timoshenko, R. V., Chmelyuk, N. S., Vadekhina, V. V., Kuanaeva, R. M., Dubrovin, E. V., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.10.561649 · Cited by 1
Connecting genomic and proteomic signatures of amyloid burden in the brainPreprint
Puerta, R., de Rojas, I., García‐González, P., Olivé, C., Sotolongo‐Grau, Ó., García‐Sánchez, A., García‐Gutiérrez, F., Montrreal, L., Tartari, J. P., Sanabria, Á., et al. (2024) · medRxiv · doi:10.1101/2024.09.06.24313124 · Cited by 1
BrainVAE: Exploring the role of white matter BOLD in preclinical Alzheimer’s disease classificationPreprint
Li, Y., Xu, L., Zuo, L., Chang, Y., Ding, Z., Anderson, A. W., Schilling, K. G., Gore, J. C., Gao, Y., & Initiative, T. A. D. N. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.07.652697 · Cited by 1
Molecular Imaging in Alzheimer Clinical Trials
Schmidt, M. E., Matthews, D. C., & Staelens, S. G. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00020-4
Optimization of Aseptic Production in PET Radiopharmaceuticals for Compliance to the Most Current GMP
Kao, C. K. (2017) · Springer eBooks · doi:10.1007/978-981-10-3349-0_3
Editorial Introduction to the Special Issue from the International Symposium on Biomarkers for Alzheimer’s Disease and Related Disorders
Sabbagh, M. N. (2017) · Neurology and Therapy · doi:10.1007/s40120-017-0068-6
Self-citation
Neuroimaging in Dementia
Ong, K. T. (2018) · OBM Geriatrics · doi:10.21926/obm.geriatr.1803011
Neuro-PET – ein Update
Beyer, L., & Rominger, A. (2018) · Der Nuklearmediziner · doi:10.1055/a-0621-3227
The Racoon Eye Sign in the Investigation of Dementia Using 18F-Florbetaben
Ordidge, K., Gandy, N., Arshad, M., & Win, Z. (2019) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000002502
Imagerie métabolique et moléculaire : l’exemple des maladies neurodégénératives
Gabelle, A. (2018) · Bulletin de l'Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)30217-1
PET and CSF amyloid-β status are differently predicted by patient features: Information from discordant casesPreprint
Reimand, J., de Wilde, A., Teunissen, C. E., Zwan, M. D., Windhorst, A. D., Boellaard, R., Barkhof, F., van der Flier, W. M., Scheltens, P., van Berckel, B. N. M., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/673467
Limitations of amyloid imaging in Alzheimer's disease
Weidman, D. A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815868-5.00031-1
Associations of Amyloid Deposition and FDG Uptake in Aging and Cognitively Impaired Elders With and Without Moderate to Severe Periventricular White Matter Hyperintensities Using Simple Machine Learning Techniques
Zukotynski, K. (2020) · TSpace (University of Toronto)
Positron emission tomography imaging agents for evaluating the pathologic features of Alzheimer's disease and drug development
Huang, Y. H., Jia, H., & Bao, W. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816475-4.00013-6
Discovery-Based Transcriptome and Translatome Profiling Reveals Molecular Pathways in the Pathogenesis of Alzheimer’s Disease
McKeever, P. M. (2018) · TSpace (University of Toronto)
Prognostic Impact of 18-F-Florbetaben Amyloid PET Imaging in Patients with Isolated Increases in Cerebrospinal Fluid Phospho-Tau Biomarkers: A Longitudinal Study
Jardel, A., Hopes, L., Malaplate, C., Roch, V., Manca, C., Jonveaux, T., & Verger, A. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201435
ALZHEIMER DISEASE PREDICTION THROUGH UNSUPERVISED CLASSIFICATION
(2020) · Journal of Xidian University · doi:10.37896/jxu14.4/186
Correlación entre el metabolismo de la glucosa cerebral (18F-FDG) y el flujo sanguíneo cerebral con marcadores de amiloide (18F-florbetapir) en práctica clínica: evidencias preliminares
Albano, D., Premi, E., Peli, A., Camoni, L., Bertagna, F., Turrone, R., Borroni, B., Calhoun, V. D., Rodella, C. A., Magoni, M., et al. (2021) · Revista Española de Medicina Nuclear e Imagen Molecular · doi:10.1016/j.remn.2021.02.004
Regional Associations of Cortical Superficial Siderosis and β-Amyloid-Positron-Emission-Tomography Positivity in Patients With Cerebral Amyloid Angiopathy
Finze, A., Wahl, H., Janowitz, D., Büerger, K., Linn, J., Rominger, A., Stoecklein, S., Bartenstein, P., Wollenweber, F. A., Catak, C., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.786143
Faculty Opinions recommendation of Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
Perani, D. (2017) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.727195707.793537453
Medial temporal tau can be a predictor for amyloid-ß positivity in mild cognitive impairmentPreprint
Cho, H., Baek, M. S., Lee, H. S., Choi, J. Y., Lee, J., Ryu, Y. H., Lee, M. S., & Lyoo, C. H. (2020) · doi:10.21203/rs.3.rs-16213/v1
Estudo prospectivo dos perfis neuropsicológicos e de neuroimagem molecular e estrutural em coortes de idosos cognitivamente normais, com declínio cognitivo subjetivo e com desempenho excepcional de memória (SuperAgers)
Studart‐Neto, A. (2022) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2022.tde-19072022-144906
Caudate-anchored cognitive connectivity pursuant to orthostatic hypotension in early Parkinson diseasePreprint
Yoo, S., Ha, S., Oh, Y., Ryu, D.-W., Yoo, J.-Y., Lee, K.-S., & Kim, J. (2022) · Research Square · doi:10.21203/rs.3.rs-2156308/v1
A Novel Dual Time-Point Unified Amyloid MRI/PET Data Analysis Technique
Vekariya, V., & Kumari, A. (2023) · International Conference on Artificial Intelligence and Smart Communication (AISC) · doi:10.1109/aisc56616.2023.10084979
Linking the Meso and Macroscale Determinants of Cerebral AgeingPreprint
Paolo, R. D., Deery, H. A., & Jamadar, S. D. (2023) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/8n4ud
Amyloid PET Radiopharmaceuticals and Imaging for Clinical and Research Applications in Thailand
Siriprapa, T., Thientunyakit, T., & Gelovani, J. G. (2023) · Siriraj Medical Journal/San Sirirat · doi:10.33192/smj.v75i9.263161
Extensive Frontal Focused Ultrasound-Mediated Blood-Brain Barrier Opening for the Treatment of Alzheimer’s Disease: An Open-Label Prospective StudyPreprint
Chang, K. W., Kang, S. W., Jeon, S., Ye, B. S., & Chang, J. W. (2024) · Research Square · doi:10.21203/rs.3.rs-3806289/v1

Authors: Sabri, O., Sabbagh, M. N., Seibyl, J., Barthel, H., Akatsu, H., Ouchi, Y., Senda, K., Murayama, S., Ishii, K., Takao, M., Beach, T. G., Rowe, C. C., Leverenz, J. B., Ghetti, B., Ironside, J. W., Catafau, A. M., Stephens, A. W., Mueller, A., Koglin, N., Hoffmann, A., Roth, K., Reininger, C., Schulz‐Schaeffer, W. J., & Florbetaben Phase 3 Study Group
Affiliations: University Hospital Leipzig (DE)
Banner Sun Health Research Institute (US)
Molecular Neuroimaging LLC New Haven CT USA
Nagoya City University (JP)
Hamamatsu University (JP)
Koseikai Hospital Toyohashi Japan
Tokyo Metropolitan Institute of Gerontology (JP)
Institute of Brain and Blood Vessels (JP)
The University of Melbourne (AU)
University of Washington (US)
Indiana University Indianapolis (US)
University of Edinburgh (GB)
Piramal (Germany) (DE)
Piramal Imaging GmbH Berlin Germany
Bayer (Germany) (DE)
Universitätsmedizin Göttingen (DE)
Corresponding author: Sabri, Osama
ORCID: Sabri, Osama
Sabbagh, Marwan N.
Seibyl, John
Barthel, Henryk
Akatsu, Hiroyasu
Ouchi, Yasuomi
Murayama, Shigeo
Ishii, Kenji
Takao, Masaki
Beach, Thomas G.
Rowe, Christopher C.
Leverenz, James B.
Ghetti, Bernardino
Ironside, James W.
Stephens, Andrew W.
Koglin, Norman
Roth, Katrin
Schulz‐Schaeffer, Walter J.
Venue: Alzheimer's & Dementia
Publisher: Wiley
Published: 2015-03-27
Volume: 11
Issue: 8
Pages: 964-974
ISSN: 1552-5260 (ISSN-L)
1552-5279
DOI: 10.1016/j.jalz.2015.02.004
OpenAlex: W2169508236
Cited by: 602
References: 33
Citations by year: 2026: 57 · 2025: 64 · 2024: 59 · 2023: 50 · 2022: 56 · 2021: 64 · 2020: 61 · 2019: 46 · 2018: 42 · 2017: 47 · 2016: 42 · 2015: 13
FWCI: 39.00
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc-nd
creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
Locations: Alzheimer s & Dementia (publishedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
GRO (submittedVersion)
Funders: Bioscript Medical
Piramal Imaging S.A
Bayer Pharma AG
Piramal Imaging S.A.
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Keywords: florbetaben, amyloid PET
MeSH terms: Aged, Aged, 80 and over, Alzheimer Disease, Analysis of Variance, Aniline Compounds, Brain, Diagnosis, Female, Humans, Image Processing, Computer-Assisted, Magnetic Resonance Imaging, Male, Middle Aged, Psychiatric Status Rating Scales, Radiography, ROC Curve, Stilbenes, Cohort Studies, Amyloid beta-Peptides, Positron-Emission Tomography, Plaque, Amyloid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks